Gonzenbach, R R; Zoerner, B; Schnell, L; Weinmann, O; Mir, A K; Schwab, M E (2012). Delayed anti-nogo-a antibody application after spinal cord injury shows progressive loss of responsiveness. Journal of Neurotrauma, 29(3):567-578.
Schnell, L; Hunanyan, A S; Bowers, W J; Horner, P J; Federoff, H J; Gullo, M; Schwab, M E; Mendell, L M; Arvanian, V L (2011). Combined delivery of Nogo-A antibody, neurotrophin-3 and the NMDA-NR2d subunit establishes a functional 'detour' in the hemisected spinal cord. European Journal of Neuroscience, 34(8):1256-1267.
Willi, R; Weinmann, O; Winter, C; Klein, J; Sohr, R; Schnell, L; Yee, B K; Feldon, J; Schwab, M E (2010). Constitutive genetic deletion of the growth regulator Nogo-A induces schizophrenia-related endophenotypes. Journal of Neuroscience, 30(2):556-567.
Arvanian, V L; Schnell, L; Loutan, L; Golshani, R; Hunanyan, A; Ghosh, A; Pearse, D D; Robinson, J K; Schwab, M E; Fawcett, J W; Mendell, L M (2009). Chronic spinal hemisection in rats induces a progressive decline in transmission in uninjured fibers to motoneurons. Experimental Neurology:471-480.
Maier, I C; Ichiyama, R M; Courtine, G; Schnell, L; Lavrov, I A; Edgerton, V R; Schwab, M E (2009). Differential effects of anti-Nogo-A antibody treatment and treadmill training in rats with incomplete spinal cord injury. Brain: A Journal of Neurology, 132(Pt 6):1426-1440.
Müllner, A; Gonzenbach, R R; Weinmann, O; Schnell, L; Liebscher, T; Schwab, M E (2008). Lamina-specific restoration of serotonergic projections after Nogo-A antibody treatment of spinal cord injury in rats. European Journal of Neuroscience, 27(2):326-333.